检索结果 - Rebecca Ellston

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores

    Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores 由 Claire Ditchfield, Victoria Johnson, Anthony Tighe, Rebecca Ellston, Carolyn Haworth, Trevor Johnson, Andrew Mortlock, Nicholas Keen, Stephen S. Taylor

    出版 2003
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for <i>PIK3CA</i>-Dependent Breast Cancers

    Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for <i>PIK3CA</i>-Dependent Breast Cancers 由 Kevin Hudson, Urs J. Hancox, Cath Trigwell, Robert McEwen, Urszula M. Polanska, Myria Nikolaou, Pablo Morentin Gutierrez, Alvaro Avivar‐Valderas, Oona Delpuech, Phillippa Dudley, Lyndsey Hanson, Rebecca Ellston, Alys Jones, Marie Cumberbatch, Sabina Cosulich, Lara Ward, Francisco Cruzalegui, Stephen Green

    出版 2016
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel

    Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel 由 Urs J. Hancox, Sabina Cosulich, Lyndsey Hanson, Cath Trigwell, Carol Lenaghan, Rebecca Ellston, Hannah Dry, Claire Crafter, Bernard Barlaam, Martina Fitzek, Paul D. Smith, Donald Ogilvie, Celina M. D’Cruz, Lillian Castriotta, Stephen R. Wedge, Lara Ward, Steve Powell, Mandy Lawson, Barry R. Davies, Elizabeth A. Harrington, Emily Foster, Marie Cumberbatch, Stephen Green, Simon T. Barry

    出版 2014
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with <i>In vitro</i> and <i>In vivo</i> Antitumor Activity

    AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with <i>In vitro</i> and <i>In vivo</i> Antitumor Activity 由 Christine M. Chresta, Barry R. Davies, Ian Hickson, Tom Harding, Sabina Cosulich, Susan E. Critchlow, John P. Vincent, Rebecca Ellston, Darren Jones, Patrizia Sini, Dominic I. James, Zoë Howard, Phillippa Dudley, Gareth Hughes, Lisa M. Smith, Sharon Maguire, Marc Hummersone, Karine Malagu, Keith Menear, Richard O. Jenkins, Matt Jacobsen, Graeme C.M. Smith, Sylvie M. Guichard, Martin Pass

    出版 2009
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  5. 5
    Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo

    Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo 由 Susan Ashton, Young Ho Song, James J. Nolan, Elaine Cadogan, J. A. H. Murray, Rajesh Odedra, John R. Foster, Peter A. Hall, Susan C. Low, Paula Taylor, Rebecca Ellston, Urszula M. Polanska, Joanne Wilson, Colin Howes, Aaron Smith, Richard J. A. Goodwin, John G. Swales, Nicole Strittmatter, Zoltán Takáts, Anna Nilsson, Per E. Andrén, Dawn Trueman, Mike Walker, Corinne Reimer, Greg Troiano, Donald M. Parsons, David De Witt, Marianne Ashford, Jeff Hrkach, Stephen E. Zale, Philip J. Jewsbury, Simon T. Barry

    出版 2016
    获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: